|View printer-friendly version|
Spring Bank Pharmaceuticals Reports Third Quarter Financial Results
“We continued to make good progress this past quarter with the announcement of positive results from the third cohort of our ACHIEVE Phase 2 HBV trial with inarigivir, our orally-available selective immunomodulator. We are encouraged that we continue to observe dose-dependent efficacy for inarigivir at escalating doses that have been generally well-tolerated and safe. Additionally, we were pleased to see Gilead expand our clinical trial collaboration to add additional cohorts to its trial investigating inarigivir in combination with tenofovir alafenamide in treatment-naïve chronic HBV patients,” said
2018 Third Quarter and Recent Highlights
2018 Third Quarter Financial Results
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.